AR and neoplasm: These results are consistent with our prior observations of PTxR cells continuing to derive benefit from abemaciclib + ET and highlight recent reports which have identified both a potential tumor suppressive and oncogenic role for the androgen receptor in ER+ breast cancer [31,32,33].